Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML)

Results of the EWOG-MDS/EBMT trial

Franco Locatelli, Peter Nöllke, Marco Zecca, Elisabeth Korthof, Edoardo Lanino, Christina Peters, Andrea Pession, Hartmut Kabisch, Cornelio Uderzo, Carmen S. Bonfim, Peter Bader, Dagmar Dilloo, Jan Stary, Alexandra Fischer, Tom Révész, Monika Führer, Henrik Hasle, Monika Trebo, Marry M. Van Den Heuvel-Eibrink, Susanna Fenu & 5 others Brigitte Strahm, Giovanna Giorgiani, Mario Regazzi Bonora, Ulrich Duffner, Charlotte M. Niemeyer

Research output: Contribution to journalArticle

205 Citations (Scopus)

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) is the only proven curative therapy for juvenile myelomonocytic leukemia (JMML). We, the European Working Group on Childhood MDS (EWOG-MDS) and the European Blood and Marrow Transplantation (EBMT) Group, report the outcome of 100 children (67 boys and 33 girls) with JMML given unmanipulated HSCT after a preparative regimen including busulfan, cyclophosphamide, and melphalan. Forty-eight and 52 children received transplants from an HLA-identical relative or an unrelated donor (UD), respectively. The source of hematopoietic stem cells was bone marrow, peripheral blood, and cord blood in 79, 14, and 7 children, respectively. Splenectomy had been performed before HSCT in 24 children. The 5-year cumulative incidence of transplantation-related mortality and leukemia recurrence was 13% and 35%, respectively. Age older than 4 years predicted an increased risk of disease recurrence. The 5-year probability of event-free survival for children given HSCT from either a relative or a UD was 55% and 49%, respectively (P = NS), with median observation time of patients alive being 40 months (range, 6 to 144). In multivariate analysis, age older than 4 years and female sex predicted poorer outcome. Results of this study compare favorably with previously published reports. Disease recurrence remains the major cause of treatment failure. Outcome of UD-HSCT recipients is comparable to that of children receiving transplants from an HLA-identical sibling.

Original languageEnglish
Pages (from-to)410-419
Number of pages10
JournalBlood
Volume105
Issue number1
DOIs
Publication statusPublished - Jan 1 2005

Fingerprint

Juvenile Myelomonocytic Leukemia
Hematopoietic Stem Cell Transplantation
Stem cells
Blood
Transplantation
Bone Marrow
Unrelated Donors
Transplants
Recurrence
Busulfan
Melphalan
Splenectomy
Hematopoietic Stem Cells
Treatment Failure
Fetal Blood
Cyclophosphamide
Disease-Free Survival
Siblings
Bone
Leukemia

ASJC Scopus subject areas

  • Hematology

Cite this

Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML) : Results of the EWOG-MDS/EBMT trial. / Locatelli, Franco; Nöllke, Peter; Zecca, Marco; Korthof, Elisabeth; Lanino, Edoardo; Peters, Christina; Pession, Andrea; Kabisch, Hartmut; Uderzo, Cornelio; Bonfim, Carmen S.; Bader, Peter; Dilloo, Dagmar; Stary, Jan; Fischer, Alexandra; Révész, Tom; Führer, Monika; Hasle, Henrik; Trebo, Monika; Van Den Heuvel-Eibrink, Marry M.; Fenu, Susanna; Strahm, Brigitte; Giorgiani, Giovanna; Bonora, Mario Regazzi; Duffner, Ulrich; Niemeyer, Charlotte M.

In: Blood, Vol. 105, No. 1, 01.01.2005, p. 410-419.

Research output: Contribution to journalArticle

Locatelli, F, Nöllke, P, Zecca, M, Korthof, E, Lanino, E, Peters, C, Pession, A, Kabisch, H, Uderzo, C, Bonfim, CS, Bader, P, Dilloo, D, Stary, J, Fischer, A, Révész, T, Führer, M, Hasle, H, Trebo, M, Van Den Heuvel-Eibrink, MM, Fenu, S, Strahm, B, Giorgiani, G, Bonora, MR, Duffner, U & Niemeyer, CM 2005, 'Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): Results of the EWOG-MDS/EBMT trial', Blood, vol. 105, no. 1, pp. 410-419. https://doi.org/10.1182/blood-2004-05-1944
Locatelli, Franco ; Nöllke, Peter ; Zecca, Marco ; Korthof, Elisabeth ; Lanino, Edoardo ; Peters, Christina ; Pession, Andrea ; Kabisch, Hartmut ; Uderzo, Cornelio ; Bonfim, Carmen S. ; Bader, Peter ; Dilloo, Dagmar ; Stary, Jan ; Fischer, Alexandra ; Révész, Tom ; Führer, Monika ; Hasle, Henrik ; Trebo, Monika ; Van Den Heuvel-Eibrink, Marry M. ; Fenu, Susanna ; Strahm, Brigitte ; Giorgiani, Giovanna ; Bonora, Mario Regazzi ; Duffner, Ulrich ; Niemeyer, Charlotte M. / Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML) : Results of the EWOG-MDS/EBMT trial. In: Blood. 2005 ; Vol. 105, No. 1. pp. 410-419.
@article{b760c858006045c9b422a12f77ec9d1c,
title = "Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): Results of the EWOG-MDS/EBMT trial",
abstract = "Allogeneic hematopoietic stem cell transplantation (HSCT) is the only proven curative therapy for juvenile myelomonocytic leukemia (JMML). We, the European Working Group on Childhood MDS (EWOG-MDS) and the European Blood and Marrow Transplantation (EBMT) Group, report the outcome of 100 children (67 boys and 33 girls) with JMML given unmanipulated HSCT after a preparative regimen including busulfan, cyclophosphamide, and melphalan. Forty-eight and 52 children received transplants from an HLA-identical relative or an unrelated donor (UD), respectively. The source of hematopoietic stem cells was bone marrow, peripheral blood, and cord blood in 79, 14, and 7 children, respectively. Splenectomy had been performed before HSCT in 24 children. The 5-year cumulative incidence of transplantation-related mortality and leukemia recurrence was 13{\%} and 35{\%}, respectively. Age older than 4 years predicted an increased risk of disease recurrence. The 5-year probability of event-free survival for children given HSCT from either a relative or a UD was 55{\%} and 49{\%}, respectively (P = NS), with median observation time of patients alive being 40 months (range, 6 to 144). In multivariate analysis, age older than 4 years and female sex predicted poorer outcome. Results of this study compare favorably with previously published reports. Disease recurrence remains the major cause of treatment failure. Outcome of UD-HSCT recipients is comparable to that of children receiving transplants from an HLA-identical sibling.",
author = "Franco Locatelli and Peter N{\"o}llke and Marco Zecca and Elisabeth Korthof and Edoardo Lanino and Christina Peters and Andrea Pession and Hartmut Kabisch and Cornelio Uderzo and Bonfim, {Carmen S.} and Peter Bader and Dagmar Dilloo and Jan Stary and Alexandra Fischer and Tom R{\'e}v{\'e}sz and Monika F{\"u}hrer and Henrik Hasle and Monika Trebo and {Van Den Heuvel-Eibrink}, {Marry M.} and Susanna Fenu and Brigitte Strahm and Giovanna Giorgiani and Bonora, {Mario Regazzi} and Ulrich Duffner and Niemeyer, {Charlotte M.}",
year = "2005",
month = "1",
day = "1",
doi = "10.1182/blood-2004-05-1944",
language = "English",
volume = "105",
pages = "410--419",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "1",

}

TY - JOUR

T1 - Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML)

T2 - Results of the EWOG-MDS/EBMT trial

AU - Locatelli, Franco

AU - Nöllke, Peter

AU - Zecca, Marco

AU - Korthof, Elisabeth

AU - Lanino, Edoardo

AU - Peters, Christina

AU - Pession, Andrea

AU - Kabisch, Hartmut

AU - Uderzo, Cornelio

AU - Bonfim, Carmen S.

AU - Bader, Peter

AU - Dilloo, Dagmar

AU - Stary, Jan

AU - Fischer, Alexandra

AU - Révész, Tom

AU - Führer, Monika

AU - Hasle, Henrik

AU - Trebo, Monika

AU - Van Den Heuvel-Eibrink, Marry M.

AU - Fenu, Susanna

AU - Strahm, Brigitte

AU - Giorgiani, Giovanna

AU - Bonora, Mario Regazzi

AU - Duffner, Ulrich

AU - Niemeyer, Charlotte M.

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Allogeneic hematopoietic stem cell transplantation (HSCT) is the only proven curative therapy for juvenile myelomonocytic leukemia (JMML). We, the European Working Group on Childhood MDS (EWOG-MDS) and the European Blood and Marrow Transplantation (EBMT) Group, report the outcome of 100 children (67 boys and 33 girls) with JMML given unmanipulated HSCT after a preparative regimen including busulfan, cyclophosphamide, and melphalan. Forty-eight and 52 children received transplants from an HLA-identical relative or an unrelated donor (UD), respectively. The source of hematopoietic stem cells was bone marrow, peripheral blood, and cord blood in 79, 14, and 7 children, respectively. Splenectomy had been performed before HSCT in 24 children. The 5-year cumulative incidence of transplantation-related mortality and leukemia recurrence was 13% and 35%, respectively. Age older than 4 years predicted an increased risk of disease recurrence. The 5-year probability of event-free survival for children given HSCT from either a relative or a UD was 55% and 49%, respectively (P = NS), with median observation time of patients alive being 40 months (range, 6 to 144). In multivariate analysis, age older than 4 years and female sex predicted poorer outcome. Results of this study compare favorably with previously published reports. Disease recurrence remains the major cause of treatment failure. Outcome of UD-HSCT recipients is comparable to that of children receiving transplants from an HLA-identical sibling.

AB - Allogeneic hematopoietic stem cell transplantation (HSCT) is the only proven curative therapy for juvenile myelomonocytic leukemia (JMML). We, the European Working Group on Childhood MDS (EWOG-MDS) and the European Blood and Marrow Transplantation (EBMT) Group, report the outcome of 100 children (67 boys and 33 girls) with JMML given unmanipulated HSCT after a preparative regimen including busulfan, cyclophosphamide, and melphalan. Forty-eight and 52 children received transplants from an HLA-identical relative or an unrelated donor (UD), respectively. The source of hematopoietic stem cells was bone marrow, peripheral blood, and cord blood in 79, 14, and 7 children, respectively. Splenectomy had been performed before HSCT in 24 children. The 5-year cumulative incidence of transplantation-related mortality and leukemia recurrence was 13% and 35%, respectively. Age older than 4 years predicted an increased risk of disease recurrence. The 5-year probability of event-free survival for children given HSCT from either a relative or a UD was 55% and 49%, respectively (P = NS), with median observation time of patients alive being 40 months (range, 6 to 144). In multivariate analysis, age older than 4 years and female sex predicted poorer outcome. Results of this study compare favorably with previously published reports. Disease recurrence remains the major cause of treatment failure. Outcome of UD-HSCT recipients is comparable to that of children receiving transplants from an HLA-identical sibling.

UR - http://www.scopus.com/inward/record.url?scp=19944428598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944428598&partnerID=8YFLogxK

U2 - 10.1182/blood-2004-05-1944

DO - 10.1182/blood-2004-05-1944

M3 - Article

VL - 105

SP - 410

EP - 419

JO - Blood

JF - Blood

SN - 0006-4971

IS - 1

ER -